|
1.
|
|
11 p, 1.1 MB |
Autosomal dominant polycystic kidney disease in young adults
/
Martínez, Víctor (Hospital Universitario Virgen de la Arrixaca) ;
Furlano, Monica (Institut d'Investigació Biomèdica Sant Pau) ;
Sans, Laia (Hospital del Mar (Barcelona, Catalunya)) ;
Pulido, Lissett (Hospital Universitari Joan XXIII de Tarragona) ;
García, Rebeca (Hospital La Mancha-Centro) ;
Pérez-Gómez, Maria Vanessa (Universidad Autónoma de Madrid) ;
Sánchez-Rodríguez, Jinny (Universidad Autónoma de Madrid) ;
Blasco Pelicano, Miquel (Hospital Clínic i Provincial de Barcelona) ;
Castro-Alonso, Cristina (Hospital Universitario Doctor Peset) ;
Fernández-Fresnedo, Gema (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
Robles, Nicolás Roberto (Hospital Universitario de Badajoz) ;
Valenzuela, María Pau ;
Naranjo, Javier (Hospital Universitario Puerta del Ma) ;
Martín, Nadiam (Hospital Universitari de Girona Doctor Josep Trueta) ;
Pilco, Melissa (Hospital Universitari de Girona Doctor Josep Trueta) ;
Agraz Pamplona, Irene (Hospital Universitari Vall d'Hebron) ;
González-Rodríguez, Juan David (Hospital Universitario Santa Lucía) ;
Panizo, Nayara (Hospital Universitari i Politècnic La Fe (València)) ;
Fraga Rodríguez, Gloria María (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Fernández, Loreto (Hospital Príncipe de Asturias) ;
López, María Teresa (Hospital Universitario Rey Juan Carlos (Madrid)) ;
Dall'Anese, Cecilia (Hospital San Pedro (La Rioja)) ;
Ortiz, Alberto (Universidad Autónoma de Madrid) ;
Torra Balcells, Roser (Institut d'Investigació Biomèdica Sant Pau) ;
Universitat Autònoma de Barcelona
The clinical manifestations of autosomal dominant polycystic kidney disease (ADPKD) usually appear in adulthood, however pediatric series report a high morbidity. The objective of the study was to analyze the clinical characteristics of ADPKD in young adults. [...]
2022 -  10.1093/ckj/sfac251
Clinical Kidney Journal, Vol. 16 (november 2022) , p. 985-995
|
|
|
2.
|
|
11 p, 389.0 KB |
Creatine Kinase Elevation in Autosomal Dominant Polycystic Kidney Disease Patients on Tolvaptan Treatment
/
Rodríguez-Espinosa, Diana (Hospital Clínic i Provincial de Barcelona) ;
Broseta, José Jesús (Hospital Clínic i Provincial de Barcelona) ;
Bastida, C. (Hospital Clínic i Provincial de Barcelona) ;
Álvarez-Mora, María Isabel (Hospital Clínic i Provincial de Barcelona) ;
Nicolau, Carlos (Hospital Clínic i Provincial de Barcelona) ;
Alvarez, Cristina (Hospital Clínic i Provincial de Barcelona) ;
Agraz Pamplona, Irene (Hospital Universitari Vall d'Hebron) ;
Sánchez-Baya, Maya (Institut d'Investigació Biomèdica Sant Pau) ;
Furlano, Monica (Institut d'Investigació Biomèdica Sant Pau) ;
Ruiz, César (Institut d'Investigació Biomèdica Sant Pau) ;
Quintana, Luis F. (Hospital Clínic i Provincial de Barcelona) ;
Piñeiro, Gastón Julio (Hospital Clínic i Provincial de Barcelona) ;
Poch, Esteban (Hospital Clínic i Provincial de Barcelona) ;
Torra Balcells, Roser (Institut d'Investigació Biomèdica Sant Pau) ;
Blasco Pelicano, Miquel (Hospital Clínic i Provincial de Barcelona) ;
Universitat Autònoma de Barcelona
Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary cause of end-stage kidney disease. Currently, tolvaptan is the only treatment that has proven to delay disease progression. [...]
2022 - 10.1159/000526368
Nephron. Clinical Practice, Vol. 147 (september 2022) , p. 152-157
|
|
|
3.
|
|
13 p, 1.4 MB |
The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy
/
Fernández-Juárez, Gema (Hospital Universitario Fundación Alcorcón) ;
Rojas-Rivera, Jorge E. (Hospital Universitario Fundación Jiménez Díaz) ;
Logt, Anne-Els van de (Radboud University Medical Center) ;
Justino, Joana (Université Côte d'Azur. Institut de Pharmacologie Moléculaire et Cellulaire (Valbonne, França)) ;
Sevillano Prieto, Angel Manuel (Hospital Universitario 12 de Octubre (Madrid)) ;
Caravaca-Fontan, Fernando (Instituto de Investigación Sanitaria Hospital 12 de Octubre (i+12)) ;
Ávila, Ana (Hospital Universitari Doctor Peset (València)) ;
Rabasco, Cristina (Hospital Universitario Reina Sofía (Còrdova, Espanya)) ;
Cabello, Virginia (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Varela, Alfonso (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ;
Díaz Encarnación, Montserrat Mercedes (Institut d'Investigació Biomèdica Sant Pau) ;
Martín-Reyes, Guillermo (Hospital Regional Universitario de Málaga) ;
Goicoechea, Marian (Hospital General Universitario Gregorio Marañón) ;
Quintana, Luis F. (Centro de Referencia en Enfermedad Glomerular Compleja del Sistema Nacional de Salud) ;
Agraz Pamplona, Irene (Hospital Universitari Vall d'Hebron) ;
Gómez-Martino, Juan Ramón (Hospital San Pedro de Alcántara) ;
Cao, Mercedes (Complejo Hospitalario Universitario de A Coruña) ;
Rodríguez-Moreno, Antolina (Hospital Clínico San Carlos (Madrid)) ;
Rivas, Begoña (Hospital Universitario La Paz (Madrid)) ;
Galeano Alvarez, Cristina (Hospital Universitario Ramón y Cajal (Madrid)) ;
Bonet, Jose (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Romera, Ana (Hospital General de Ciudad Real) ;
Shabaka, Amir (Hospital Universitario Fundación Alcorcón) ;
Plaisier, Emmanuelle (Centre de Référence Maladies Rares Syndrome Néphrotique Idiopathique (Niça, França)) ;
Espinosa, Mario (Hospital Universitario Reina Sofía (Còrdova, Espanya)) ;
Egido de los Rios, Jesus (Hospital Universitario Fundación Jiménez Díaz) ;
Segarra-Medrano, Alfonso (Hospital Universitari Vall d'Hebron) ;
Lambeau, Gérard (Institut de Pharmacologie Moléculaire et Cellulaire (Valbonne, França)) ;
Ronco, Pierre (Centre de Référence Maladies Rares Syndrome Néphrotique Idiopathique (Niça, França)) ;
Wetzels, Jack (Radboud University Medical Center) ;
Praga, Manuel (Instituto de Investigación Sanitaria Hospital 12 de Octubre (i+12)) ;
Caravaca-Fontan, Fernando (Hospital Universitario 12 de Octubre (Madrid)) ;
Trujillo, Hernando (Hospital Universitario 12 de Octubre (Madrid)) ;
Gutiérrez, Eduardo (Hospital Universitario 12 de Octubre (Madrid)) ;
Ortiz, Alberto (Hospital Universitario Fundación Jiménez Díaz) ;
Goicoechea, Marian (Hospital General Universitario Gregorio Marañón) ;
Verdalles, Úrsula (Hospital General Universitario Gregorio Marañón) ;
Segarra, Alfons (Hospital Universitari Vall d'Hebron) ;
Perea, Lara (Hospital Universitari Vall d'Hebron) ;
Valera, Ildefonso (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ;
Martín, Mónica (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ;
Pérez Valdivia, Miguel Angel (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Blasco, Miquel Angel (Hospital Clínic i Provincial de Barcelona) ;
López Muñiz, Andrés (Complejo Hospitalario Universitario de A Coruña) ;
Malek, Tamara (Hospital Universitari Doctor Peset (València)) ;
DaSilva Santos, Iara ;
Bonet, Jordi (Institut Germans Trias i Pujol) ;
Navarro, Maruja Isabel (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Huerta, Ana (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Rodríguez-Paternina, Ezequiel (Hospital Universitario de Getafe (Madrid)) ;
Vigil, Ana (Hospital Universitario Severo Ochoa) ;
Alcázar, Roberto (Hospital Universitario Infanta Leonor) ;
Paraíso, Vicente (Hospital Universitario del Henares ( Madrid)) ;
Barrio, Vicente (Hospital Universitario Infanta Sofía (San Sebastián de los Reyes)) ;
Hofstra, Julia (Radboud University Medical Center) ;
Universitat Autònoma de Barcelona
A cyclical corticosteroid-cyclophosphamide regimen is recommended for patients with primary membranous nephropathy at high risk of progression. We hypothesized that sequential therapy with tacrolimus and rituximab is superior to cyclical alternating treatment with corticosteroids and cyclophosphamide in inducing persistent remission in these patients. [...]
2021 - 10.1016/j.kint.2020.10.014
Kidney International, Vol. 99 Núm. 4 (april 2021) , p. 986-998
|
|
|
4.
|
|
9 p, 2.6 MB |
A Specific Tubular ApoA-I Distribution Is Associated to FSGS Recurrence after Kidney Transplantation
/
Jacobs-Cachá, Conxita (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Puig-Gay, Natalia (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Vergara, Ander (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Gabaldon, Maria-Alejandra (Hospital Universitari Vall d'Hebron) ;
Sellarés, Joana (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Villena-Ortiz, Yolanda (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Agraz Pamplona, Irene (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Moreso, Francesc (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Soler, María José (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Seron, Daniel (Universitat Autònoma de Barcelona. Departament de Medicina) ;
López-Hellín, Joan (Hospital Universitari Vall d'Hebron. Institut de Recerca)
A major complication of primary focal segmental glomerulosclerosis (FSGS) is its recurrence after kidney transplantation that happens in 30 to 40% of the patients. The diagnosis of these relapses is not always easy as the histological lesions are not highly specific and appear after the proteinuria increase. [...]
2021 - 10.3390/jcm10102174
Journal of clinical medicine, Vol. 10 (may 2021)
|
|
|
5.
|
|
18 p, 2.3 MB |
Biomarkers in Fabry Disease. Implications for Clinical Diagnosis and Follow-up
/
Carnicer-Cáceres, Clara (Hospital Universitari Vall d'Hebron) ;
Arranz-Amo, Jose Antonio (Hospital Universitari Vall d'Hebron) ;
Cea-Arestin, Cristina (Hospital Universitari Vall d'Hebron) ;
Camprodon-Gomez, Maria (Hospital Universitari Vall d'Hebron) ;
Moreno-Martinez, David (Lysosomal Storage Disorders Unit, Royal Free Hospital NHS Foundation Trust and University College London, London WC1E 6BT, UK) ;
Lucas-Del-Pozo, Sara (UCL Institute of Neurology (Regne Unit)) ;
Moltó Abad, Marc (Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina) ;
Tigri-Santiña, Ariadna (Hospital Universitari Vall d'Hebron) ;
Agraz Pamplona, Irene (Hospital Universitari Vall d'Hebron) ;
Rodriguez-Palomares, Jose F.. (Hospital Universitari Vall d'Hebron) ;
Hernández-Vara, Jorge (Hospital Universitari Vall d'Hebron) ;
Armengol-Bellapart, Mar (Hospital Universitari Vall d'Hebron) ;
Del Toro, Mireia (Hospital Universitari Vall d'Hebron) ;
Pintos-Morell, Guillem (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Universitat Autònoma de Barcelona
Fabry disease (FD) is a lysosomal storage disorder caused by deficient alpha-galactosidase A activity in the lysosome due to mutations in the GLA gene, resulting in gradual accumulation of globotriaosylceramide and other derivatives in different tissues. [...]
2021 - 10.3390/jcm10081664
Journal of clinical medicine, Vol. 10 (april 2021)
|
|
|
6.
|
|
13 p, 423.1 KB |
Off-label use of rituximab in patients with different types of nephropathies in a tertiary hospital : a retrospective study
/
Sans-Pola, Carla (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Agustí Escasany, M. Antònia (Maria Antònia) (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Bosch Gil, Josep Àngel (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Danés Carreras, Immaculada (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) ;
Alerany, Carmen (Hospital Universitari Vall d'Hebron) ;
Agraz Pamplona, Irene (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Off-label use of rituximab is commonly requested for patients with resistant nephropathies. The outcomes and tolerability of rituximab in adult patients with nephropathy treated at our hospital (from 2013 to 2018) were described. [...]
2021 - 10.3390/jcm10214941
Journal of clinical medicine, Vol. 10 Núm. 21 (november 2021) , p. 4941
|
|
|
7.
|
|
16 p, 1.1 MB |
The New Era for Reno-Cardiovascular Treatment in Type 2 Diabetes
/
García-Carro, Clara (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Vergara, Ander (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Agraz Pamplona, Irene (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Jacobs-Cachá, Conxita (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Espinel Garuz, Eugenia (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Seron, Daniel (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Soler, María José (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Universitat Autònoma de Barcelona
Diabetic kidney disease (DKD) is the leading cause of end-stage renal disease in the developed world. Until 2016, the only treatment that was clearly demonstrated to delay the DKD was the renin-angiotensin system blockade, either by angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. [...]
2019 - 10.3390/jcm8060864
Journal of clinical medicine, Vol. 8 (june 2019)
|
|
|
8.
|
|
8 p, 257.9 KB |
COVID-19 in CKD Patients : Lessons from 553 CKD Patients with Biopsy-Proven Kidney Disease
/
Román, Juan León (Hospital Universitari Vall d'Hebron) ;
García-Carro, Clara (Hospital Universitari Vall d'Hebron) ;
Agraz Pamplona, Irene (Hospital Universitari Vall d'Hebron) ;
Toapanta, Néstor (Hospital Universitari Vall d'Hebron) ;
Vergara, Ander (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Gabaldón, Alejandra (Hospital Universitari Vall d'Hebron) ;
Torres, Irina B. (Hospital Universitari Vall d'Hebron) ;
Bury, Roxana (Hospital Universitari Vall d'Hebron) ;
Baldallo, Cinthia (Hospital Universitari Vall d'Hebron) ;
Seron, Daniel (Hospital Universitari Vall d'Hebron) ;
Soler, María José (Hospital Universitari Vall d'Hebron) ;
Universitat Autònoma de Barcelona
Chronic kidney disease (CKD) patients infected with COVID-19 are at risk of serious complications such as hospitalization and death. The prognosis and lethality of COVID-19 infection in patients with established kidney disease has not been widely studied. [...]
2021 - 10.1159/000515714
Kidney & blood pressure research, june 2021, p. 1-8
|
|
|
9.
|
|
7 p, 443.9 KB |
Acute tubulointerstitial nephritis induced by checkpoint inhibitors versus classical acute tubulointerstitial nephritis : are they the same disease?
/
Draibe, Juliana B. (Hospital Universitari de Bellvitge) ;
García-Carro, Clara (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Martinez-Valenzuela, Laura (Hospital Universitari de Bellvitge) ;
Agraz Pamplona, Irene (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Fulladosa, Xavier (Hospital Universitari de Bellvitge) ;
Bolufer Cardona, Mónica (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Tango, Ariel (Hospital Universitari de Bellvitge) ;
Torras, Joan (Universitat de Barcelona) ;
Soler, María José (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Universitat Autònoma de Barcelona
The incidence of acute tubulointerstitial nephritis (ATIN) related to drugs has dramatically increased over recent years. A new subtype of ATIN, apparently different from classical drug-related ATIN, has emerged that has been related to the administration of immune checkpoint inhibitors (ICIs). [...]
2020 - 10.1093/ckj/sfaa027
Clinical Kidney Journal, Vol. 14 (may 2020) , p. 884-890
|
|
|
10.
|
|
10 p, 625.3 KB |
Challenges in primary focal segmental glomerulosclerosis diagnosis : from the diagnostic algorithm to novel biomarkers
/
Jacobs-Cachá, Conxita (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Vergara, Ander (Hospital Universitari Vall d'Hebron) ;
García-Carro, Clara (Red de Investigación Renal) ;
Agraz Pamplona, Irene (Red de Investigación Renal) ;
Toapanta, Néstor (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Ariceta Iraola, Gema (Hospital Universitari Vall d'Hebron) ;
Moreso, Francesc (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Seron, Daniel (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
López-Hellín, Joan (Hospital Universitari Vall d'Hebron) ;
Soler, María José (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Universitat Autònoma de Barcelona
Primary or idiopathic focal segmental glomerulosclerosis (FSGS) is a kidney entity that involves the podocytes, leading to heavy proteinuria and in many cases progresses to end-stage renal disease. Idiopathic FSGS has a bad prognosis, as it involves young individuals who, in a considerably high proportion (∼15%), are resistant to corticosteroids and other immunosuppressive treatments as well. [...]
2020 - 10.1093/ckj/sfaa110
Clinical Kidney Journal, Vol. 14 (august 2020) , p. 482-491
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
